HRP20220024T1 - Tekuća neurotoksinska formulacija stabilizirana triptofanom ili tirozinom - Google Patents
Tekuća neurotoksinska formulacija stabilizirana triptofanom ili tirozinom Download PDFInfo
- Publication number
- HRP20220024T1 HRP20220024T1 HRP20220024TT HRP20220024T HRP20220024T1 HR P20220024 T1 HRP20220024 T1 HR P20220024T1 HR P20220024T T HRP20220024T T HR P20220024TT HR P20220024 T HRP20220024 T HR P20220024T HR P20220024 T1 HRP20220024 T1 HR P20220024T1
- Authority
- HR
- Croatia
- Prior art keywords
- liquid preparation
- botulinum neurotoxin
- disorders
- tryptophan
- preparation according
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims 19
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title claims 9
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 title claims 7
- 101710138657 Neurotoxin Proteins 0.000 title claims 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title claims 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title claims 3
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002581 neurotoxin Substances 0.000 title 1
- 231100000618 neurotoxin Toxicity 0.000 title 1
- 108030001720 Bontoxilysin Proteins 0.000 claims 12
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims 11
- 206010040954 Skin wrinkling Diseases 0.000 claims 8
- 229960004799 tryptophan Drugs 0.000 claims 7
- 230000037303 wrinkles Effects 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 210000001061 forehead Anatomy 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000001488 sodium phosphate Substances 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 1
- 208000030137 articulation disease Diseases 0.000 claims 1
- 108010069022 botulinum toxin type D Proteins 0.000 claims 1
- 108010069023 botulinum toxin type E Proteins 0.000 claims 1
- 108010069038 botulinum toxin type F Proteins 0.000 claims 1
- 108010069071 botulinum toxin type G Proteins 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229940113124 polysorbate 60 Drugs 0.000 claims 1
- 229910001414 potassium ion Inorganic materials 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 108010074523 rimabotulinumtoxinB Proteins 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Tekući pripravak, naznačen time, što sadrži proteinski neurotoksin, surfaktant, aminokiselinu odabranu od triptofana i tirozina, pufer koji sadrži natrijeve, kloridne i fosfatne ione,
pri čemu navedeni tekući pripravak ima pH vrijednost između 5,5 i 8,
te time, da navedeni pripravak ne sadrži proteine dobivene iz životinja, i
gdje je navedeni tekući pripravak stabilan u vremenskom periodu od dva mjeseca pri temperaturi od 2-8 °C.
2. Tekući pripravak prema patentnom zahtjevu 1, naznačen time, što je navedeni surfaktant neionski surfaktant.
3. Tekući pripravak prema patentnom zahtjevu 2, naznačen time, što navedeni neionski surfaktant jest polisorbat, poželjno polisorbat 20, polisorbat 60 ili polisorbat 80.
4. Tekući pripravak prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, što navedena aminokiselina je triptofan, poželjno L-triptofan.
5. Tekući pripravak prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, što navedeni pufer nadalje sadrži kalijeve ione;
i/ili
time, da navedeni pripravak ima pH vrijednost između 6,0 i 7,5; i/ili
time, da ne dolazi do više od 30% gubitaka izvanstanične proteolitske aktivnosti u dodatnom periodu od 2, 3, 6, 12, 18, 24 ili 36 mjeseci na 5 °C.
6. Tekući pripravak prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, što proteinski neurotoksin je botulinski neurotoksin koji je odabran od prirodnog botulinskog neurotoksina u obliku kompleksa, prirodnog botulinskog neurotoksina velike čistoće i rekombinantnog botulinskog neurotoksina;
pri čemu poželjno, navedeni botulinski neurotoksin je rekombinantni botulinski neurotoksin koji se bira od botulinskog neurotoksina A, B, C, D, E, F ili G, modificiranog botulinskog neurotoksina i kimernog botulinskog neurotoksina.
7. Tekući pripravak prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, što navedeni tekući pripravak sadrži:
• 4 do 10000 LD50 jedinica botulinskog neurotoksina po mL,
• 0,001 do 15% v/v polisorbata,
• 0,1 do 5 mg/mL triptofana,
• 10 do 500 mM NaCl,
• 1 do 50 mM KCl,
• 1 do 100 mM natrijevog fosfata,
ima pH vrijednost između 5,5 i 8, te je stabilan tijekom 12 mjeseci na 5 °C.
8. Tekući pripravak prema patentnom zahtjevu 7, naznačen time, što navedeni tekući pripravak sadrži:
• 10 do 2000 LD50 jedinica botulinskog neurotoksina po mL,
• 0,05 do 0,2% v/v polisorbata 80,
• 0,1 do 5 mg/mL triptofana,
• 25 do 300 mM NaCl,
• 1 do 10 mM KCl,
• 2 do 50 mM natrijevog fosfata,
ima pH vrijednost između 6,0 i 7,5, te je stabilan tijekom 18 mjeseci na 5 °C.
9. Tekući pripravak prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, što je za uporabu u liječenju.
10. Tekući pripravak prema patentnom zahtjevu 9, naznačen time, što je za uporabu u liječenju ili prevenciji muskularnih poremećaja, neuromuskularnih poremećaja, neuroloških poremećaja, oftalmoloških poremećaja, poremećaja boli, psiholoških poremećaja, artikulacijskih poremećaja, upalnih poremećaja, endokrinih poremećaja ili uroloških poremećaja.
11. Uporaba tekućeg pripravka prema bilo kojem od patentnih zahtjeva 1 do 8, naznačena time, što je za estetsku medicinu, primjerice za obradu ili prevenciju naborane kože, posebice nabora na licu kao što su linije mrštenja lica, konturne bore oko očiju, horizontalne linije mrštenja na čelu, linije spuštenih usana, bore na vratu (platizmalne vrpce), bore na bradi (musculus mentalis, narančina kora, namreškana brada), naborane linije čela, bore poput „izgrebane kože“, postupak podizanja nosa ili bore od spavanja.
12. Uporaba aminokiseline odabrane od triptofana i tirozina, naznačena time, što služi za zaštitu proteinskog neurotoksina od propadanja u tekućem pripravku u kojemu nema proteina dobivenih iz životinja, pri čemu tekući pripravak ostaje stabilan u vremenskom periodu od dva mjeseca na 2-8 °C.
13. Uporaba prema patentnom zahtjevu 12, naznačena time, što navedena aminokiselina jest triptofan.
14. Uporaba prema patentnom zahtjevu 12 ili 13, naznačena time, što navedeni proteinski neurotoksin jest botulinski neurotoksin.
15. Uporaba prema patentnom zahtjevu 12, naznačena time, što se navedena aminokiselina upotrebljava u kombinaciji sa surfaktantom i puferom koji sadrži natrijeve, kloridne i fosfatne ione, i navedeni tekući pripravak ima pH vrijednost između 5,5 i 8.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016062085 | 2016-05-27 | ||
| EP20152386.7A EP3679946B1 (en) | 2016-05-27 | 2017-05-26 | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220024T1 true HRP20220024T1 (hr) | 2022-04-01 |
Family
ID=56289455
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220024TT HRP20220024T1 (hr) | 2016-05-27 | 2017-05-26 | Tekuća neurotoksinska formulacija stabilizirana triptofanom ili tirozinom |
| HRP20202070TT HRP20202070T1 (hr) | 2016-05-27 | 2020-12-28 | Tekuća neurotoksinska formulacija stabilizirana s triptofanom ili tirozinom |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20202070TT HRP20202070T1 (hr) | 2016-05-27 | 2020-12-28 | Tekuća neurotoksinska formulacija stabilizirana s triptofanom ili tirozinom |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US20190183988A1 (hr) |
| EP (3) | EP4026532A1 (hr) |
| JP (1) | JP7053498B2 (hr) |
| KR (2) | KR102423739B1 (hr) |
| CN (2) | CN111701010B (hr) |
| AR (1) | AR108631A1 (hr) |
| AU (1) | AU2017270359B2 (hr) |
| BR (1) | BR112018074311A2 (hr) |
| CA (1) | CA3025437A1 (hr) |
| CY (2) | CY1124237T1 (hr) |
| DK (2) | DK3463432T3 (hr) |
| EA (1) | EA038124B1 (hr) |
| ES (2) | ES2846350T3 (hr) |
| GE (1) | GEP20207139B (hr) |
| HR (2) | HRP20220024T1 (hr) |
| HU (2) | HUE057640T2 (hr) |
| IL (2) | IL285190B (hr) |
| LT (2) | LT3463432T (hr) |
| MX (1) | MX2018014631A (hr) |
| PL (2) | PL3679946T3 (hr) |
| PT (2) | PT3679946T (hr) |
| RS (2) | RS62832B1 (hr) |
| RU (1) | RU2741497C9 (hr) |
| SA (1) | SA518400513B1 (hr) |
| SG (1) | SG11201810561YA (hr) |
| SI (2) | SI3679946T1 (hr) |
| TW (1) | TWI777955B (hr) |
| UA (1) | UA123679C2 (hr) |
| WO (1) | WO2017203038A1 (hr) |
| ZA (1) | ZA201807904B (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
| CN102300584A (zh) | 2008-12-31 | 2011-12-28 | 雷文斯治疗公司 | 可注射的肉毒杆菌毒素制剂 |
| MX366344B (es) | 2009-06-25 | 2019-07-05 | Revance Therapeutics Inc | Formulaciones de toxina botulinica libres de albumina. |
| US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| AU2017326253B2 (en) | 2016-09-13 | 2021-10-21 | Allergan, Inc. | Stabilized non-protein clostridial toxin compositions |
| EP3728295A1 (en) * | 2017-12-20 | 2020-10-28 | Allergan, Inc. | Botulinum toxin cell binding domain polypeptides and methods of use for treatments of fibrosis associated disorders |
| TW202112348A (zh) * | 2019-06-07 | 2021-04-01 | 英商益普生生物製藥有限公司 | 中度至極重度眉間紋及眼角外紋之治療 |
| TW202333767A (zh) * | 2022-01-14 | 2023-09-01 | 英商益普生生物製藥有限公司 | 中度至極重度眉間紋及眼角外紋之治療 |
| WO2023156389A1 (en) | 2022-02-15 | 2023-08-24 | Merz Pharma Gmbh & Co. Kgaa | Liquid botulinum toxin formulation and use thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW518219B (en) * | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| EP1253932B1 (en) * | 2000-02-08 | 2005-04-27 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
| US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
| AU2001236005A1 (en) * | 2000-02-29 | 2001-09-12 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilized over long time |
| US6627602B2 (en) * | 2001-11-13 | 2003-09-30 | Duke University | Preventing desensitization of receptors |
| DE10333317A1 (de) | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| GB2416122A (en) * | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| AU2005274822B2 (en) * | 2004-07-26 | 2008-10-30 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
| WO2006013370A1 (en) * | 2004-08-04 | 2006-02-09 | Ipsen Limited | Pharmaceutical composition containing botulinum neurotoxin a2 |
| US20080220021A1 (en) | 2005-02-14 | 2008-09-11 | Pankaj Modi | Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis |
| FR2902341B1 (fr) | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
| US8617568B2 (en) * | 2007-07-10 | 2013-12-31 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
| US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| EP2715355B1 (en) | 2011-06-01 | 2017-03-08 | Biomadison, Inc. | Non-fret botulinum assay |
| RU2616281C2 (ru) | 2011-09-29 | 2017-04-13 | СЕЛЛСНЭП, ЭлЭлСи | Композиции и способы испытаний на токсикогенность |
| KR101357999B1 (ko) * | 2012-03-20 | 2014-02-03 | 함종욱 | 보툴리눔 에이형 독소의 액상제품 |
| US20160243232A1 (en) | 2013-09-30 | 2016-08-25 | Galderma S.A. | Prostate cancer treatment |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
-
2017
- 2017-05-26 KR KR1020227012437A patent/KR102423739B1/ko active IP Right Grant
- 2017-05-26 CN CN202010742639.2A patent/CN111701010B/zh active Active
- 2017-05-26 HU HUE20152386A patent/HUE057640T2/hu unknown
- 2017-05-26 TW TW106117499A patent/TWI777955B/zh active
- 2017-05-26 UA UAA201811606A patent/UA123679C2/uk unknown
- 2017-05-26 MX MX2018014631A patent/MX2018014631A/es unknown
- 2017-05-26 EP EP21211390.6A patent/EP4026532A1/en active Pending
- 2017-05-26 PT PT201523867T patent/PT3679946T/pt unknown
- 2017-05-26 DK DK17728095.5T patent/DK3463432T3/da active
- 2017-05-26 EA EA201892493A patent/EA038124B1/ru unknown
- 2017-05-26 US US16/304,986 patent/US20190183988A1/en not_active Abandoned
- 2017-05-26 ES ES17728095T patent/ES2846350T3/es active Active
- 2017-05-26 DK DK20152386.7T patent/DK3679946T3/da active
- 2017-05-26 JP JP2018562171A patent/JP7053498B2/ja active Active
- 2017-05-26 LT LTEP17728095.5T patent/LT3463432T/lt unknown
- 2017-05-26 HR HRP20220024TT patent/HRP20220024T1/hr unknown
- 2017-05-26 RS RS20220045A patent/RS62832B1/sr unknown
- 2017-05-26 PL PL20152386T patent/PL3679946T3/pl unknown
- 2017-05-26 LT LTEP20152386.7T patent/LT3679946T/lt unknown
- 2017-05-26 SI SI201731069T patent/SI3679946T1/sl unknown
- 2017-05-26 SG SG11201810561YA patent/SG11201810561YA/en unknown
- 2017-05-26 IL IL285190A patent/IL285190B/en unknown
- 2017-05-26 AU AU2017270359A patent/AU2017270359B2/en active Active
- 2017-05-26 RU RU2018142149A patent/RU2741497C9/ru active
- 2017-05-26 HU HUE17728095A patent/HUE052023T2/hu unknown
- 2017-05-26 WO PCT/EP2017/062785 patent/WO2017203038A1/en unknown
- 2017-05-26 SI SI201730582T patent/SI3463432T1/sl unknown
- 2017-05-26 KR KR1020187037095A patent/KR102399451B1/ko active IP Right Grant
- 2017-05-26 GE GEAP201714939A patent/GEP20207139B/en unknown
- 2017-05-26 EP EP17728095.5A patent/EP3463432B1/en active Active
- 2017-05-26 PT PT177280955T patent/PT3463432T/pt unknown
- 2017-05-26 ES ES20152386T patent/ES2911124T3/es active Active
- 2017-05-26 PL PL17728095T patent/PL3463432T3/pl unknown
- 2017-05-26 CA CA3025437A patent/CA3025437A1/en active Pending
- 2017-05-26 CN CN201780044565.1A patent/CN109562148A/zh active Pending
- 2017-05-26 EP EP20152386.7A patent/EP3679946B1/en active Active
- 2017-05-26 RS RS20201596A patent/RS61340B1/sr unknown
- 2017-05-26 BR BR112018074311A patent/BR112018074311A2/pt unknown
- 2017-05-29 AR ARP170101464A patent/AR108631A1/es unknown
-
2018
- 2018-11-21 IL IL263173A patent/IL263173B/en unknown
- 2018-11-22 ZA ZA2018/07904A patent/ZA201807904B/en unknown
- 2018-11-26 SA SA518400513A patent/SA518400513B1/ar unknown
-
2020
- 2020-12-28 HR HRP20202070TT patent/HRP20202070T1/hr unknown
-
2021
- 2021-01-05 CY CY20211100001T patent/CY1124237T1/el unknown
- 2021-06-28 US US17/304,888 patent/US20230190892A9/en not_active Abandoned
-
2022
- 2022-01-25 CY CY20221100057T patent/CY1124916T1/el unknown
-
2023
- 2023-02-24 US US18/173,991 patent/US20230181702A1/en not_active Abandoned
- 2023-09-28 US US18/476,731 patent/US20240050539A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20202070T1 (hr) | Tekuća neurotoksinska formulacija stabilizirana s triptofanom ili tirozinom | |
| US10195076B2 (en) | Head-mounted device providing diagnosis and treatment and multisensory experience | |
| Jeffries et al. | The effects of menthol on exercise performance and thermal sensation: A meta-analysis | |
| Happle et al. | The lines of Blaschko on the head and neck | |
| Pinto-Bonilla et al. | A randomized crossover study comparing trehalose/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye syndrome | |
| MX2010003774A (es) | Formulaciones oftalmicas acuosas. | |
| ES2665620T3 (es) | Composiciones anticaspa, y métodos de uso de las mismas | |
| HRP20240050T1 (hr) | Formulacije tpp1 i postupci liječenja bolesti cln2 | |
| US20170112667A1 (en) | Head-mounted device providing diagnosis and treatment and multisensory experience | |
| EP2802331B1 (en) | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide f2 alpha agonists | |
| Smith et al. | Madarosis: a qualitative study to assess perceptions and experience of Australian patients with early breast cancer treated with taxane-based chemotherapy | |
| MX2021012579A (es) | Composiciones farmaceuticas a base de peptidos de colageno y dispositivos y metodos de produccion y uso de los mismos. | |
| MX2019013453A (es) | Extractos de plantas con actividades antidiabeticas y otras actividades utiles. | |
| JP5383223B2 (ja) | おむつかぶれ改善剤 | |
| JP2009280557A (ja) | 安定なカフェイン含有水系組成物 | |
| WO2017104537A1 (ja) | アミノ酸配合顔用皮膚外用剤 | |
| MA50991B1 (fr) | Composition topique ophtalmique comprenent de l'acide dobesilique pour le traitement des maladies du segment postérieur de l' il | |
| CN104622702A (zh) | 含有丙三醇和甘氨酸的组合物 | |
| Giannaccare et al. | A novel osmoprotectant tear substitute for the treatment of dry eye disease | |
| Suttle et al. | Negligible impact on posture from 5-diopter vertical yoked prisms | |
| Boulet et al. | Is there a role for bronchial thermoplasty in the treatment of asthma? | |
| Niimi et al. | Effect of facial attractiveness on clothing attractiveness ratings by gender. | |
| JP2019131517A (ja) | 内服液 | |
| Macrea et al. | Reducing pain by moving? A commentary on Ferrè et al. 2013 | |
| DE602007009283D1 (de) | En und ihre verwendung |